

Amendment
Serial No. 09/864,685
Page 7 of 11

REMARKS

The above-listed claim amendments along with the following remarks are fully responsive to the final Office Action set forth above. This Amendment places the application in condition for allowance, or in better position for appeal, and entry of this Amendment and reconsideration of the application is requested.

By this Amendment, claims 1, 2, 4, 6, 10, 31, 39, and 49 are amended. Claims 2, 4, 6, and 10 are amended only to correct typographical errors. No new matter is introduced into the application by the claim amendments. Claims 7, 33, 41, and 50 are cancelled. After entry of this Amendment, claims 1-4, 6, 8, 10, 31, 32, 34-40, 42-49, and 51-55 are pending. The Examiner indicated that claims 46-48 are allowable, and that claims 7, 8, 10, 33-37, 41-45, 50, 51, and 55 would be allowable if rewritten in independent form.

Claim Rejections – 35 U.S.C. § 112

The Examiner rejected claims 1-4, 6, 31, 32, 38-40, 49 and 52-54 under 35 U.S.C. § 112, as being broader than the scope of enablement provided by the disclosure. The Examiner states that the claims are not adequately enabled for the term “modulator of cellular glutathione effective to decrease cellular glutathione levels.”

The Examiner did not reject any claims in which a specific chemical entity was named as the modulator of cellular glutathione levels. Rather, the Examiner objected to such claims, and indicated that those claims would be allowable if written in independent form.

The Applicant respectfully differs with the Examiner regarding the scope of enablement provided by the disclosure. However, in the interests of expediting prosecution, independent claims 1, 31, 39, and 49 are amended to recite that the modulator of cellular glutathione is selected from the group consisting of ethacrynic acid, L-buthionine-S,R-sulfoximine, diethylmaleate, 2-cyclohexene-1-one, and 1-chloro-2,4-dinitrobenzene. Claims 7, 33, 41, and 50 are accordingly cancelled.

The present claim amendments are not a disclaimer of scope of the claimed invention. The Applicant reserves the right to pursue, by way of a continuation application, claims that are not limited to the recited modulators of cellular glutathione levels.

Withdrawal of all rejections is requested.

Amendment
Serial No. 09/864,685
Page 8 of 11


Conclusion

This Amendment places the application in condition for allowance, or in better position for appeal, and entry of this Amendment and reconsideration of the application is requested. After entry of this Amendment, all claims are in condition for allowance and a notice to that effect is respectfully requested.

Respectfully Submitted,

ZOLTAN KISS

By:


Sean B. Mahoney, #51,984
FAEGRE & BENSON LLP
2200 Wells Fargo Center
90 South Seventh Street
Minneapolis, MN 55402-3901
612/766-6845

Dated: October 22, 2003

M2:20578452.01

RECEIVED
CENTRAL FAX CENTER
OCT 22 2003

OFFICIAL